$2.83
12.38% yesterday
Nasdaq, Dec 24, 10:59 pm CET
ISIN
US59564R2031
Symbol
BDRX

Midatech Pharma Plc Sponsored ADR Stock price

$2.83
-1.49 34.49% 1M
-6.38 69.27% 6M
-37.67 93.01% YTD
-40.06 93.40% 1Y
-57,605.17 100.00% 3Y
-719,997.17 100.00% 5Y
-84,399,997.17 100.00% 10Y
-146,999,997.17 100.00% 20Y
Nasdaq, Closing price Wed, Dec 24 2025
-0.40 12.38%
ISIN
US59564R2031
Symbol
BDRX
Industry

Key metrics

Basic
Market capitalization
$2.0m
Enterprise Value
$-2.8m
Net debt
positive
Cash
$5.5m
Shares outstanding
6.2b
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
0.2
P/B
0.1
Financial Health
Equity Ratio
56.3%
Return on Equity
-68.8%
ROCE
-72.8%
ROIC
-97.5%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-11.8m | -
EBIT
$-12.1m | $-18.6m
Net Income
$-8.4m | $-21.8b
Free Cash Flow
$-14.9m
Growth (TTM | estimate)
Revenue
-100.0% | -
EBITDA
-13.3% | -
EBIT
-12.5% | -49.8%
Net Income
8.7% | -282,412.4%
Free Cash Flow
-24.8%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$0.0
FCF per Share
$0.0
Short interest
20.0%
Employees
13
Rev per Employee
$0.0
Show more

Is Midatech Pharma Plc Sponsored ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,079 stocks worldwide.

Midatech Pharma Plc Sponsored ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Midatech Pharma Plc Sponsored ADR forecast:

6x Buy
86%
1x Hold
14%

Analyst Opinions

7 Analysts have issued a Midatech Pharma Plc Sponsored ADR forecast:

Buy
86%
Hold
14%

Financial data from Midatech Pharma Plc Sponsored ADR

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 5.58 5.58
1% 1%
-
- Research and Development Expense 6.63 6.63
23% 23%
-
-12 -12
13% 13%
-
- Depreciation and Amortization 0.35 0.35
5% 5%
-
EBIT (Operating Income) EBIT -12 -12
12% 12%
-
Net Profit -8.40 -8.40
9% 9%
-

In millions USD.

Don't miss a Thing! We will send you all news about Midatech Pharma Plc Sponsored ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Midatech Pharma Plc Sponsored ADR Stock News

Neutral
GlobeNewsWire
7 days ago
December 18, 2025 Biodexa Announces Pricing of $10 Million Public Offering Biodexa Pharmaceuticals PLC, (Nasdaq: BDRX) (“Biodexa” or the “Company”), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, today announced the pricing of a best efforts public offering of an aggregate of (i) 157,000 units (the ...
Neutral
GlobeNewsWire
24 days ago
December 1, 2025 Biodexa Announces Enrolment of First European Patients into Pivotal Phase 3 Serenta Trial in FAP Biodexa Pharmaceuticals PLC (“Biodexa” or “the Company”), (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, is pleased to announce the enrolment of the first three patients ...
Neutral
GlobeNewsWire
about one month ago
November 24, 2025 Biodexa Activates First European Site for Registrational Phase 3 Serenta Trial in FAP Biodexa Pharmaceuticals PLC (Nasdaq: BDRX) announced today that the University of Bonn, Germany is now actively screening patients for the Phase 3 Serenta clinical trial evaluating eRapa in familial adenomatous polyposis (FAP). This marks the first European site activation for the registratio...
More Midatech Pharma Plc Sponsored ADR News

Company Profile

Midatech Pharma Plc commercializes oncology treatments and cancer supportive care products through its U.S. commercial organization, Midatech Pharma US. The company engages in the development of pharmaceutical products utilizing its nanomedicine and sustained release technologies. Its pipeline includes MTD119, MTX102, MTD201 and MTX110. Midatech Pharma was founded on September 12, 2014 and is headquartered in Cardiff, the United Kingdom.

Head office United Kingdom
CEO Stephen Stamp
Employees 13
Founded 2000
Website www.biodexapharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today